Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Javitt, JC., Zlateva, GP., Earnshaw, S., Pleil, AM., Graham, C., Brogan, A., Shah, SN., & Adamis, AR. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers
Article

Far-right and Jihadi terrorism within the United States
Article

Internalizing and externalizing subtypes of alcohol misuse and their relation to drinking motives
Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders